Horizon Dishes Out Million Dollars to get Arrowhead's RNAi Drug
Arrowhead Pharmaceuticals and Horizon Therapeutics have announced a research and development collaboration to advance the treatment landscape for uncontrolled gout.
Under the terms and conditions, Arrowhead is bound to receive an upfront sum of USD40 million while lending the exclusive global rights of its short interfering RNA (siRNA) treatment to Horizon. The treatment aims to target xanthine dehydrogenase (XDH) for the treatment of uncontrolled gout. Besides, Arrowhead will also be eligible to receive monetization gains on development, regulatory and commercial milestones of upto $660 million, as...
